Skip to main content

Advertisement

SpringerLink
Log in

Sunitinib-induced sudden hearing loss

  • SHORT REPORT
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Raymond E, Dahan L, Raoul JL, et al. (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501–513

    Article  CAS  PubMed  Google Scholar 

  2. Naranjo CA, Busto U, Sellers EM, et al. (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:239–245

    Article  CAS  PubMed  Google Scholar 

  3. Reck M, Frickhofen N, Cedres S, et al. (2010) Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation study. Lung Cancer 70:180–187. doi:10.1016/j.lungcan.2010.01.016

    Article  PubMed  Google Scholar 

  4. Camidge DR, Blais N, Jonker DJ, et al. (2013) Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma. Cancer Chemother Pharmacol 71:307–319. doi:10.1007/s00280-012-2008-6

    Article  CAS  PubMed  Google Scholar 

  5. Kapiteijn E, Brand A, Kroep J, et al. (2007) Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. Ann Oncol: official journal of the European Society for Medical Oncology / ESMO 18:1745–1747. doi:10.1093/annonc/mdm454

    Article  CAS  Google Scholar 

  6. Frangie C, Lefaucheur C, Medioni J, et al. (2007) Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma. The Lancet Oncology 8:177–178. doi:10.1016/S1470-2045(07)70037-2

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Hospices Civils de Lyon, Hôpital Edouard Herriot, 69437, Lyon cedex 03, France

    Kathleen Dekeister, Emmanuelle Graillot & Thomas Walter

  2. Department of ENT (ear, nose and throat), Hospices Civils de Lyon, Hôpital Edouard Herriot, 69437, Lyon cedex 03, France

    Mickaël Durbec

  3. Department of Medical Biology and Pathology, Institut Gustave Roussy, 94805, Villejuif cedex, France

    Jean-Yves Scoazec

  4. Université de Lyon, Université Claude Bernard Lyon 1, 69622, Villeurbanne cedex, France

    Thomas Walter

Authors
  1. Kathleen Dekeister
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emmanuelle Graillot
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mickaël Durbec
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jean-Yves Scoazec
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Thomas Walter
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kathleen Dekeister.

Ethics declarations

Conflict of interest

The authors indicated no potential conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dekeister, K., Graillot, E., Durbec, M. et al. Sunitinib-induced sudden hearing loss. Invest New Drugs 34, 792–793 (2016). https://doi.org/10.1007/s10637-016-0378-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-016-0378-z

Keywords

Search

Navigation